GLP-1 drugs cut infection risk in diabetes
Two new studies suggest GLP-1 receptor agonist drugs, used for type 2 diabetes and obesity, may significantly reduce the risk of serious infections
People with type 2 diabetes taking GLP-1 receptor agonist drugs were significantly less likely to develop tuberculosis or be hospitalized or die from infections, according to two recent studies. The research, covered by MedPage Today, adds to the growing list of potential benefits for this class of medications.
Reduced Tuberculosis Risk
An international study of more than 7 million people found those on GLP-1 drugs had a lower risk of developing tuberculosis compared to patients using other common diabetes medications. The analysis, published in Nature Communications, showed the reduced risk was consistent across several drug comparisons.
| Comparison Medication | Hazard Ratio for TB |
|---|---|
| DPP-4 inhibitors | 0.49 |
| Sulfonylureas | 0.53 |
| Metformin | 0.60 |
| SGLT2 inhibitors | 0.82 |
"These findings suggest that beyond their established metabolic benefits, GLP-1 receptor agonists may confer additional advantages in lowering infection risk," concluded Dr. Chih-Cheng Lai of Chi Mei Medical Center in Taiwan and his colleagues. The study authors pointed to preclinical data showing these drugs can enhance immune cell function in mice.
Protection Against Serious Infections
A separate real-world study focused on the GLP-1 drug tirzepatide. It involved over 50,000 U.S. adults with type 2 diabetes and atherosclerotic cardiovascular disease. Published in The BMJ, the research compared outcomes for patients on tirzepatide versus those on the DPP-4 inhibitor sitagliptin.
The study found tirzepatide was associated with substantially lower one-year risks for several infection-related outcomes.
| Infection Outcome | Hazard Ratio |
|---|---|
| Infection-related mortality | 0.40 |
| Infection-related hospitalization | 0.64 |
| Urinary tract infections | 0.83 |
| Infections in any care setting | 0.83 |
A reduction in all-cause mortality was also observed among tirzepatide users. The study was led by Dr. Nils Krüger of Harvard Medical School. His team wrote that the reduction in serious bacterial infections suggests part of the survival benefit "may reflect effects beyond atherosclerotic mechanisms."
Underlying Mechanisms and Context
The findings align with prior knowledge. People with diabetes have a higher risk for active tuberculosis. Obesity has been linked to worse outcomes from infections. Researchers believe systemic inflammation and immune dysfunction associated with obesity may drive this increased susceptibility.
The new studies support a recent umbrella review that found convincing evidence for GLP-1 medications having protective effects against infection-related outcomes. This is particularly true for serious infections.
Beyond diabetes and weight management, GLP-1 drugs like tirzepatide and semaglutide now have FDA-approved uses for conditions including chronic kidney disease and reducing major cardiovascular events. Observational studies have hinted at other potential benefits, from reducing cancer risk to helping with addictions.
Study Limitations
The tuberculosis study used data from the TriNetX international health research network from 2017 to 2025. A key limitation was a lack of data on important TB variables, which limited analysis of how GLP-1 drugs work across different disease patterns. Geographical differences in TB rates could also have influenced the results.
The tirzepatide study analyzed U.S. claims data from 2022 to 2025. Its authors noted the relatively short follow-up period could mean long-term effects are underestimated. The median patient age in that study was 70 years, 51% were women, and 85% took statins.
